Key facts
- This page summarizes Pershing Edward's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 30 Jan 2025, 17:13.
Pershing Edward - 30 Jan 2025 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
- Reporting relationship
- CEO, Director
- Issuer ticker
- PVCT
- Reported as of
- 30 Jan 2025
- Net transaction value
- -$135,000
- SEC form
- 4
- Accepted by SEC
- 30 Jan 2025, 17:13:36 UTC
- Prior SEC filing
- 22 Jan 2025
- Next SEC filing
- 19 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward Pershing
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pershing Edward filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 30 Jan 2025.
Change
- Previous filing in this sequence was filed on 22 Jan 2025.
- Current net transaction value: -$135,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PVCT
transaction
Derivative
8% Unsecured Convertible Promissory Note
Options Exercise
- Transaction value
- $135,000
- Shares
- Change %
- Price
- Shares after
- $1,990,000
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Series D-1 Convertible Preferred Stock
- Underlying amount
- 51,290
- Exercise price
- $2.86
- Footnotes
- F3, F4
PVCT
transaction
Derivative
Series D-1 Convertible Preferred Stock
Options Exercise
- Transaction value
- $0
- Shares
- +51,290
- Change %
- +2.9%
- Price
- $0.000000
- Shares after
- 1,799,634
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 512,900
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
Footnote F2
The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
Footnote F3
The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2022 Note") at any time while the 2022 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2022 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2022 Note. The 2022 Note was issued pursuant to the Issuer's 2022 Financing.
Footnote F4
On January 30, 2024, the 2022 Note was converted into 51,290 shares of Series D-1 Preferred Stock.